Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NASS 2020: Medtronic Announces First Patient Implant With InterStim Micro, Adaptix Interbody System Launch

Executive Summary

Medtronic’s next-generation InterStim Micro system for overactive bladder is more competitive with Axionics’ r-SNM system, according to an analyst. Medtronic continues to innovate as its former CEO announces retirement.

You may also be interested in...



Medtronic ‘Plays Offense’ Despite Pandemic Challenges, Q1 Results Provide Optimism

Medtronic’s revenue of $6.5bn in the first quarter of fiscal 2021 represents a 17% fall year-over-year, but it still beat analysts’ projections.

FDA Expands Indication For Axonics’ Incontinence System; Medtronic Claims Patent Infringement

The US FDA approved Axonics’ r-SNM sacral neuromodulation system for treating overactive bladder and urinary retention on 14 November. The agency approved the same device for treating chronic fecal incontinence on 9 September. Axonics expects r-SNM to rival Medtronic's InterStim II non-rechargeable sacral neuromodulation system, but Medtronic claims the r-SNM technology infringes on Medtronic’s intellectual property.

Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5M Army Award

A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132356

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel